Objective:

To evaluate the presence of antibodies against spike specific protein (RBD, receptor binding domain of spike protein) and NP (nucleoprotein) of SARS-CoV-2 virus in people who received anti-COVID-19 vaccines used in Bolivia.

Methods:

During 2021 between July and August, a cross-sectional observational study was carried out in 150 persons of both sexes who were recruited in the Hospitals: Caja de Seguro Social Militar and Caja Nacional de Salud, to detect specific antibodies against the NP and RBD proteins of the SARS-CoV-2 virus responsible for COVID-19, by means of a qualitative immunochromatographic test.

Results:

The presence of neutralizing antibodies after the administration of vaccines against SARS-CoV-2, as complete scheme, first dose, and/or history of infection, was found in 61 % of the persons grouped in the category "low occupational risk" in a heterogeneous way regarding RBD antibodies, NP or both together.

Conclusions:

The production of antibodies against the specific protein of the RBD and NP spike of the SARS-CoV-2 virus shows a heterogeneous response due to several factors such as, type of vaccine, number of doses, infection by COVID-19, antibody decline over time, sensitivity of the test and intrinsic properties of the person evaluated.

        · resumen en Español     · texto en Español     · Español ( pdf )